tbuckley/cabot-search huggingface dataset:
Trends in survival for metastatic soft-tissue sarcoma: A French Sarcoma Group (GSF) database analysis.
Authors: A. Italiano, S. Mathoulin-Pelissier, P. Terrier, A. Le Cesne, S. Bonvalot, F. Collin, J. Michels, J. Blay, J. Coindre, N. Bin Bui
Journal: Journal of Clinical Oncology (2010)

10045 Background: Treatment of metastatic soft-tissue sarcoma (STS) has evolved over the last two decades with the improvement of supportive care,theincreased use of loco-regional treatments, the widespread use of additional lines of chemotherapy and the increasing participation of STS patients (pts) in investigational agents trials. The aim of this study is to evaluate the changes in overall survival (OS) of pts with metastatic STS. Methods: 1,024 consecutive pts with synchronous (SM) or metachronous metastatic (MM) STS diagnosed between 1987 and 2006 were included prospectively in the GSF database after central histological review. Four period of diagnosis of metastatic disease were defined: P1=1987-91: n=208, P2=1992-96: n= 287, P3=1997-2001: n=285, and P4 = 2002-2006: n=244). OS was estimated by the Kaplan-Meier method. Results: The proportion of pts with SM, the time to diagnosisof MM and theclinical characteristics (age, sex, histological subtype, grade, site of metastasis) were similar across the four periods. There was no significant difference in the median OS times from P1 through P2 (P1 = 12.3 months (m) 95% CI [9.9-14.7]; P2 = 11.4 m 95% CI [9-13.9]). However, significant improvements were seen in the later periods: P3 = 15 m 95% CI [11.8-18.2]; P4 = 18 m 95% CI [15.3-20.7] (log-rank test: P = 0.029). The 2-year OS rate has also increased all along the study period: P1= 28.1% 95% CI [22-34.5], P2 = 32% 95% CI [26.6-37.5], P3= 33.3% 95% CI [27.8-39], P4= 38.7%, 95% CI [32.3-45]. On multivariate analysis, period of diagnosis, age, histological subtype, time to metastatic relapse, FNCLCC grade and number of metastatic sites were independent prognostic factors for OS. Conclusions: Median OS of pts with metastatic STS has improved by 50% during the last 20 years. These data should be considered for the interpretation of the results of ongoing and future STS trials. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Novartis, Pfizer, PharmaMar
TCT-493 Interventional Strategies for Coronary In-Stent Restenosis: A Hierarchical Bayesian Network Meta-Analysis of Randomized Trials
Authors: Daniele Giacoppo, Giuseppe Gargiulo, Patrizia Aruta, Piera Capranzano, Corrado Tamburino, Davide Capodanno
Journal: Journal of the American College of Cardiology (2015)
Congenital Heart Defects and Indices of Placental and Fetal Growth in a Nationwide Study of 924 422 Liveborn Infants
Authors: Niels B. Matthiesen, Tine B. Henriksen, Peter Agergaard, J. William Gaynor, Cathrine C. Bach, Vibeke E. Hjortdal, John R. Østergaard
Journal: Circulation (2016)

Congenital heart defects (CHDs) have been associated with placental anomalies. The nature and the consequences of this association remain poorly understood. We aimed to estimate the associations between all major subtypes of CHD and placental weight at birth, and the association between placental weight and measures of both overall and cerebral growth in fetuses with CHD, as well.We included all 924 422 liveborn Danish singletons, 1997 to 2011. CHD was present in 7569. We compared mean differences in placental weight z score between newborns with CHD and newborns without CHD by multivariable linear regression adjusted for potential confounders.CHD was associated with a mean z score difference of -0.04 (95% confidence interval, -0.07 to -0.02). Some subtypes were associated with smaller placental size at birth: tetralogy of Fallot, -0.45 (95% confidence interval, -0.58 to -0.31); double-outlet right ventricle, -0.48 (95% confidence interval, -0.87 to -0.10); major ventricular septal defects, -0.41 (95% confidence interval, -0.52 to -0.29). Placental weight z score was associated with birth weight and head circumference z scores in all subtypes. In the 3 mentioned subtypes, the mean deviations from the population mean head circumference and birth weight z scores were reduced by up to 66% with adjustment for placental weight z score.Three subtypes of CHD were associated with lower placental weight, and placental weight was associated with measures of both overall growth and cerebral growth in fetuses with all subtypes of CHD. In certain subtypes, the described deviations in fetal growth were reduced by up to two-thirds after adjustment for placental weight z score.
Outcomes of African American (AA) versus caucasian (CA) women with triple-negative (TN) breast cancer following preoperative anthracycline and taxane-based chemotherapy
Authors: A. Balmanoukian, Z. Zhang, S. C. Jeter, T. N. Tsangaris, A. C. Wolff, D. K. Armstrong, J. H. Fetting, M. Fackler, E. Gabrielson, V. Stearns
Journal: Journal of Clinical Oncology (2008)

11530 Background: Although AA have a lower incidence of breast cancer compared to CA, they are more likely to present with a TN phenotype and to have a higher mortality rate. Chemotherapy is the only adjuvant treatment available to women with a TN breast cancer phenotype. Data suggest that TN tumors are overall highly sensitive to preoperative chemotherapy but have a worse prognosis when compared to other breast cancer subtypes. We hypothesized that a contributing factor to a worse outcome in AA may be a poor response to anthracycline and taxane based chemotherapy. Methods: We conducted a retrospective review of treatment outcomes of women with TN breast cancer who received preoperative anthracycline and/or taxane-based regimens. We compared pathologic complete response (pCR), a surrogate marker for long-term survival, in AA to CA or other racial groups using Fisher’s exact test and logistic regression model for multivariate analysis. Disease free survival (DFS) and overall survival (OS) were compared using log-rank tests and Cox regression analyses. Results: We identified 39 women who received preoperative therapy for TN breast cancer from May 2002 to January 2007, including 13 AA, 20 CA and 6 from other racial groups (Table). AA women with TN breast cancer had a significantly worse pCR compared to women of other races before and after adjustment for patient heterogeneity. We also observed a trend toward a worse DFS and OS in AA. Conclusions: AA women with TN breast cancers have a significantly worse pCR rate following anthracycline and/or taxane based regimens. A larger sample size is required to evaluate differences in DFS and OS among the racial groups. New treatments are required for women diagnosed with TN breast cancer, especially for AA. Analysis of basal markers and gene methylation in this dataset is underway. Patient Characteristics Characteristic Race (%) P AA (N=13) CA or Other (N=26) Age < 51 85 42 0.017 Clinical Stage 3 69 38 0.035 pCR 31 77 0.014 DFS at 3-year 33 77 0.069 OS at 3- year 42 73 0.047 No significant financial relationships to disclose.
Changes to the Definition of Posttraumatic Stress Disorder in the <i>DSM-5</i>—Reply
Authors: Charles W. Hoge
Journal: JAMA Psychiatry (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study
Authors: Xiaozhou Fan, Alexander V Alekseyenko, Jing Wu, Brandilyn A Peters, Eric J Jacobs, Susan M Gapstur, Mark P Purdue, Christian C Abnet, Rachael Stolzenberg-Solomon, George Miller, Jacques Ravel, Richard B Hayes, Jiyoung Ahn
Journal: Gut (2016)

A history of periodontal disease and the presence of circulating antibodies to selected oral pathogens have been associated with increased risk of pancreatic cancer; however, direct relationships of oral microbes with pancreatic cancer have not been evaluated in prospective studies. We examine the relationship of oral microbiota with subsequent risk of pancreatic cancer in a large nested case-control study.We selected 361 incident adenocarcinoma of pancreas and 371 matched controls from two prospective cohort studies, the American Cancer Society Cancer Prevention Study II and the National Cancer Institute Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. From pre-diagnostic oral wash samples, we characterised the composition of the oral microbiota using bacterial 16S ribosomal RNA (16S rRNA) gene sequencing. The associations between oral microbiota and risk of pancreatic cancer, controlling for the random effect of cohorts and other covariates, were examined using traditional and L1-penalised least absolute shrinkage and selection operator logistic regression.Carriage of oral pathogens, Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans, were associated with higher risk of pancreatic cancer (adjusted OR for presence vs absence=1.60 and 95% CI 1.15 to 2.22; OR=2.20 and 95% CI 1.16 to 4.18, respectively). Phylum Fusobacteria and its genus Leptotrichia were associated with decreased pancreatic cancer risk (OR per per cent increase of relative abundance=0.94 and 95% CI 0.89 to 0.99; OR=0.87 and 95% CI 0.79 to 0.95, respectively). Risks related to these phylotypes remained after exclusion of cases that developed within 2 years of sample collection, reducing the likelihood of reverse causation in this prospective study.This study provides supportive evidence that oral microbiota may play a role in the aetiology of pancreatic cancer.
Intracortical microstimulation of human somatosensory cortex
Authors: Sharlene N. Flesher, Jennifer L. Collinger, Stephen T. Foldes, Jeffrey M. Weiss, John E. Downey, Elizabeth C. Tyler-Kabara, Sliman J. Bensmaia, Andrew B. Schwartz, Michael L. Boninger, Robert A. Gaunt
Journal: Science Translational Medicine (2016)

Tactile percepts were consistently elicited in the hand of a person with cervical spinal cord injury using intracortical microstimulation of the somatosensory cortex.
TCT-379 Independent and Combined Effect of Chronic Kidney Disease and Diabetes Mellitus in Women Undergoing Percutaneous Coronary Intervention with Drug-Eluting Stents: Results from a Patient-Level Pooled Analysis of Randomized Controlled Trials
Authors: Usman Baber, Gennaro Giustino, Olga Salianski, Melissa Aquino, Samantha Sartori, Giulio G. Stefanini, Philippe G. Steg, Stephan Windecker, Martin Leon, Gregg W. Stone, Marco Valgimigli, Laxmi Mehta, Rebecca Ortega, Marie-Claude Morice, Roxana Mehran
Journal: Journal of the American College of Cardiology (2015)
TCT-504 Bioresorbable Scaffold As Option For The Treatment Of Coronary In-Stent Restenosis: Result From Single-Centre Prospective Observational Study With Angiographic Follow-Up
Authors: Jarosław Wójcik, Andrzej Madejczyk, Krzysztof Wiórkowski, Marek Jankiewicz
Journal: Journal of the American College of Cardiology (2015)
Increased Eligibility for Attempting Treatment-Free Remission (TFR) with Frontline Nilotinib (NIL) vs Imatinib (IM) in Patients with Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia (CML): Results of a Stochastic Simulation Model
Authors: Francois-Xavier Mahon, An Tran-Duy, Raechelle G. Ocampo, David Ray, Estella Mendelson, Aby Buchbinder, Pascal Edrich, Sonya J. Snedecor, Giuseppe Saglio
Journal: Blood (2015)
Molecular classification of Crohn's disease reveals two clinically relevant subtypes
Authors: Matthew Weiser, Jeremy M Simon, Bharati Kochar, Adelaide Tovar, Jennifer W Israel, Adam Robinson, Gregory R Gipson, Matthew S Schaner, Hans H Herfarth, R Balfour Sartor, Dermot P B McGovern, Reza Rahbar, Timothy S Sadiq, Mark J Koruda, Terrence S Furey, Shehzad Z Sheikh
Journal: Gut (2016)

Objective The clinical presentation and course of Crohn's disease (CD) is highly variable. We sought to better understand the cellular and molecular mechanisms that guide this heterogeneity, and characterise the cellular processes associated with disease phenotypes. Design We examined both gene expression and gene regulation (chromatin accessibility) in non-inflamed colon tissue from a cohort of adult patients with CD and control patients. To support the generality of our findings, we analysed previously published expression data from a large cohort of treatment-naïve paediatric CD and control ileum. Results We found that adult patients with CD clearly segregated into two classes based on colon tissue gene expression—one that largely resembled the normal colon and one where certain genes showed expression patterns normally specific to the ileum. These classes were supported by changes in gene regulatory profiles observed at the level of chromatin accessibility, reflective of a fundamental shift in underlying molecular phenotypes. Furthermore, gene expression from the ilea of a treatment-naïve cohort of paediatric patients with CD could be similarly subdivided into colon-like and ileum-like classes. Finally, expression patterns within these CD subclasses highlight large-scale differences in the immune response and aspects of cellular metabolism, and were associated with multiple clinical phenotypes describing disease behaviour, including rectal disease and need for colectomy. Conclusions Our results strongly suggest that these molecular signatures define two clinically relevant forms of CD irrespective of tissue sampling location, patient age or treatment status.
TCT-437 Pre-planned tailored vascular access program significantly decreases the vascular complication rate
Authors: Marek Grygier, Maciej Lesiak, Anna Olasinska-Wisniewska, Aleksander Araszkiewicz, Olga Trojnarska, Anna Komosa, Marcin Misterski, Marcin Ligowski, Piotr Buczkowski, Marek Jemielity, Stefan Grajek
Journal: Journal of the American College of Cardiology (2015)
A Gene Polymorphism within the Kinase Domain of BCR-ABL and Its Effects on Sensitivity to Tyrosine Kinase Inhibitors.
Authors: Lucy C. Crossman, Thomas O’Hare, Thoralf Lange, Stephanie G. Willis, Eric P. Stoffregen, Amie S. Corbin, Stephen G. O’Brien, Michael C. Heinrich, Brian J. Druker, Peter G. Middleton, Michael W.N. Deininger
Journal: Blood (2005)
GW27-e0615 The Antibody of Recombinant cyclophilin A Attenuate myocardial inflammatory damage of Lipopolysaccharide-induced mice via down-regulation of neutrophil extracellular traps formation
Authors: Liao Jinli, Jia Xu, Yan Xiong, Ren Jiang, Ziyu Zheng, Hong Zhan
Journal: Journal of the American College of Cardiology (2016)
Impact of Anthracycline Dose in Elderly Patients with Difusse Large B Cell Lymphoma (DLBCL) at the Instituto Nacional De Cancerologia Mexico
Authors: Diana Nolasco -Medina, Mohar Alejandro, Nancy Reynoso-Noveron, Alejandro Aviles-Salas, Osvaldo Garcia, Myrna Candelaria
Journal: Blood (2015)
Receipt of Antibiotics in Hospitalized Patients and Risk for <i>Clostridium difficile</i> Infection in Subsequent Patients Who Occupy the Same Bed
Authors: Daniel E. Freedberg, Hojjat Salmasian, Bevin Cohen, Julian A. Abrams, Elaine L. Larson
Journal: JAMA Internal Medicine (2016)

To assess whether receipt of antibiotics by prior hospital bed occupants is associated with increased risk for CDI in subsequent patients who occupy the same bed.This is a retrospective cohort study of adult patients hospitalized in any 1 of 4 facilities between 2010 and 2015. Patients were excluded if they had recent CDI, developed CDI within 48 hours of admission, had inadequate follow-up time, or if their prior bed occupant was in the bed for less than 24 hours.The primary exposure was receipt of non-CDI antibiotics by the prior bed occupant and the primary outcome was incident CDI in the subsequent patient to occupy the same bed. Incident CDI was defined as a positive result from a stool polymerase chain reaction for the C difficile toxin B gene followed by treatment for CDI. Demographics, comorbidities, laboratory data, and medication exposures are reported.Among 100 615 pairs of patients who sequentially occupied a given hospital bed, there were 576 pairs (0.57%) in which subsequent patients developed CDI. Receipt of antibiotics in prior patients was significantly associated with incident CDI in subsequent patients (log-rank P < .01). This relationship remained unchanged after adjusting for factors known to influence risk for CDI including receipt of antibiotics by the subsequent patient (adjusted hazard ratio [aHR], 1.22; 95% CI, 1.02-1.45) and also after excluding 1497 patient pairs among whom the prior patients developed CDI (aHR, 1.20; 95% CI, 1.01-1.43). Aside from antibiotics, no other factors related to the prior bed occupants were associated with increased risk for CDI in subsequent patients.Receipt of antibiotics by prior bed occupants was associated with increased risk for CDI in subsequent patients. Antibiotics can directly affect risk for CDI in patients who do not themselves receive antibiotics.
A pivotal phase III trial to evaluate the efficacy and safety of adjuvant treatment with R1549 (yttrium-90-labeled HMFG1 murine monoclonal antibody) in epithelial ovarian cancer (EOC)
Authors: M. V. Seiden, B. B. Benigno
Journal: Journal of Clinical Oncology (2004)

5008 Background: EOC patients achieving a complete response (CR) after primary therapy are at substantial risk of recurrent disease. Consolidation strategies designed to improve overall survival are needed. In a small phase II study, patients treated with intraperitoneal (i.p.) R1549 following standard treatment demonstrated encouraging survival compared with a historical control group. Methods: The Study of Monoclonal AntibodyRadioimmunoTherapy (SMART) is a multinational, multicenter, randomized, phase III trial comparing standard treatment plus adjuvant R1549 with standard treatment alone. Patients with FIGO stage Ic-IV, MUC1-positive EOC achieving clinical CR with first-line therapy were randomized 1:1. Patients with no macroscopic disease at second look laparoscopy (-ve SLL), performed 4–8 weeks after completion of chemotherapy, remained on study. Patients in the active treatment arm received a single i.p. dose of 25mg R1549 (≈ 666MBq/m2; maximum dose 1110MBq); patients in the control arm received standard care. The primary endpoint was length of survival; secondary endpoints included time to relapse and safety. The study had an 80% power to detect a 15% change in survival. Results: A total of 447 patients was included in the intent to treat analysis. With a median follow-up of 3.5 years (range 1–6), 104 and 70 have relapsed and died in the active treatment arm (n=224), respectively, as compared with 98 and 61 in the control arm (n=223). Cox proportional hazards analysis of survival and time to relapse demonstrated no difference between treatment arms. Active therapy was associated with occasional, transient Grade 3/4 thrombocytopenia and neutropenia, and mild to moderate GI symptoms, abdominal discomfort, arthralgia, and myalgia. Conclusions: The single i.p. administration of R1549 after -ve SLL does not extend survival or remission in patients with EOC. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Antisoma PLC
Lymph node metastasis in breast cancer: The role of tumor markers
Authors: M. J. Lund, S. M. Graham, J. M. Liff, R. J. Coates, E. W. Flagg, X. Yuan, M. G. Lin, J. W. Eley, P. L. Porter
Journal: Journal of Clinical Oncology (2007)

21019 Background: Women diagnosed with lymph node positive breast cancer have a greater chance of recurrence and death than women with lymph node negative disease. Tumor markers are becoming increasingly important to understanding breast cancer progression, yet little is known about their relationship with lymph node status. The purpose of this study is to examine whether prognostic and novel cell-cycle tumor markers are associated with lymph node status in black and white women with invasive breast cancer. Methods: This study included 202 lymph node positive and 292 node negative women, ages 20–54 years, diagnosed with invasive breast cancer between 1990 and 1992, and previously enrolled in a population-based study in Atlanta, Georgia. Tumor specimens were centrally reviewed and evaluated for lymphovascular invasion (LVI) and Nottingham tumor grade. Expression of estrogen and progesterone receptors (ER and PR), c-ErbB-2, Ki-67, pRb, p16, p21, p27, p130/Rb2, p53, cyclin E, and cyclin D1 were centrally assayed by immunohistochemistry. Relationships between each tumor marker and lymph node status were assessed by logistic regression, after adjusting for prognostic and socio-demographic factors. Results: Several tumor markers were associated with lymph node status, but differed by tumor size. Among women with smaller tumors (≤2.0 cm), p130 (OR=0.6, 95% CI 0.4–1.0), Bcl-2 (OR=0.4, 95% CI 0.2–0.8), and cyclin D1 (OR=1.7, 95% CI 1.0–2.8) were significant predictors of positive lymph node status. Among women with tumors &gt; 2.0 cm, p53 (OR=0.5, 95% CI 0.3–0.8), and cyclin E (OR=0.4, 95% CI 0.2–0.9), and pRb (OR=1.6, (95% CI 1.0–2.6) were significant predictors. Black women with smaller tumors were 50% more likely to have lymph node metastasis. LVI and high grade remained the strongest predictors of lymph node metastasis in all regression models. Conclusions: Our findings suggest that there may be a different mechanism for lymph node spread in aggressive smaller tumors compared to larger tumors. Identifying markers for aggressive tumors could lead to the benefit of more effective treatment, particularly among black women for whom race may be a surrogate for other markers not accounted for in our study. No significant financial relationships to disclose.
Antibiotics for Acute Bronchitis
Authors: Susan M. Smith, John Smucny, Tom Fahey
Journal: JAMA (2014)

Are antibiotics associated with improved outcomes in patients with acute bronchitis?Prescribing antibiotics for acute bronchitis was associated with reduced overall and nighttime cough and with an approximately half-day reduction in duration of cough, in days feeling ill, and in days with impaired activities. However, at follow-up, there were no significant differences in patients receiving antibiotics compared with those receiving placebo in overall clinical improvements or limitations in work or other activities. There was a significant increase in adverse effects in the antibiotic group, particularly gastrointestinal symptoms.
TCT-575 Multi-Center, Post-marketing Evaluation of the Elixir DESyne® Novolimus Eluting Coronary Stent System: 1-Year Results from the EXCELLA PMCF Study
Authors: Imad A. Alhaddad, Mohammad Jarrah, Ramiro Trillo, Andres Iñiguez Romo, Ricardo A. Costa, Lynn Morrison, Sara Toyloy, Lynn Vandertie, Karl-Eugen Hauptmann
Journal: Journal of the American College of Cardiology (2015)